Blood cancers: stem cell transplant

To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers

Who can joinAdults

Age18+ years

Kind of studyPhase 2: does it work?

What it testsA medicine

The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.

Where to go

1 hospital in India taking patients for this trial.

Advanced Centre for Treatment, Research and Education in CancerNavi Mumbai, MaharashtraDirections ↗

Registry summary (technical)

Cyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant. The standard dose of this medicine is 50 mg per kg of the patient's weight given on the 3rd and the 4th day. However, using this medicine at this dose of 50 mg / kg for 2 days is associated with certain problems such as susceptibility to infections and delay in the recovery of the immune system after stem cell transplant. Therefore, several research groups across the world have tried to reduce the d…

Sponsor: Tata Memorial Centre
NCT07719946 on ClinicalTrials.gov
Last updated on the registry 22 Jul 2026 · read by us 20 Oct 2026

Blood cancers: stem cell transplant

Where to go

Need help reaching the trial team? Write to us.